Article Text

Download PDFPDF
Case of acute arthritis following SARS-CoV-2 infection
  1. Naoto Yokogawa1,2,
  2. Naoto Minematsu2,
  3. Harutaka Katano3,
  4. Tadaki Suzuki3
  1. 1 Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo, Japan
  2. 2 Department of Internal Medicine, Hino Municipal Hospital, Hino, Tokyo, Japan
  3. 3 Department of Pathology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan
  1. Correspondence to Dr Naoto Yokogawa, Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu 183-8524, Tokyo, Japan; yokogawan{at}aol.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In a recent issue of ARD, López-González and colleagues reported case series of acute arthritis during COVID-19 admission; the authors concluded that all four cases of acute arthritis in their report were due to crystal-proven gout flares or calcium pyrophosphate deposition disease.1 Here we would like to share another case of COVID-19 presenting delayed arthritis without crystal deposition.

A 57-year-old, male, Japanese patient with a history of hypertension and hyperlipidaemia was admitted to our hospital with cough, fever and malaise of 3 days’ duration. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was positive at admission on real-time (RT) PCR using nasopharyngeal swabs (SRL Inc). Chest X-rays and CT showed multiple, peripheral, ground-glass opacities …

View Full Text

Footnotes

  • Contributors NY and NM contributed to the conception and drafting of the article. All authors provided critical revision for important intellectual content and final approval.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.